LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Plasma NT-ProBNP Levels Predict Severity of Enterovirus-71 Infection

By LabMedica International staff writers
Posted on 08 Dec 2016
Print article
Image: The XE-2100 automated hematological parameters analyzer (Photo courtesy of Sysmex).
Image: The XE-2100 automated hematological parameters analyzer (Photo courtesy of Sysmex).
Hand, foot, and mouth disease (HFMD) is caused by a variety of human enteroviruses, mainly by enterovirus 71 (EV71) and coxsackievirus A16 (CA16), and is characterized by fever and vesicular exanthema on the hands, feet, and mouth.

Brain-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are released in equimolar amounts from the myocardium. Their levels increase in response to hemodynamic stress, and they have an established role in cardiovascular (vasodilation) and renal (natriuresis) physiology, conferring protection against fluid overload and hypertension.

Scientists at the Hunan Children's Hospital (Changsha, China) enrolled between January 2012 and December 2013, 282 patients from pediatric intensive care unit patients with HFMD, 183 (64.89%) were male and the median age of the cohort was 21 months. Cases were recorded as having severe HFMD if they were found to have the more serious complications including encephalitis, meningitis, acute flaccid paralysis, and cardiorespiratory failure, or died.

Venous blood sample for the detection of NT-proBNP was collected during the first hour of hospital admission and was stored immediately at −70 °C. The samples were centrifuged at 3,000 rpm for 20 minutes and analyzed using an electrochemiluminescence immunoassay (Elecsys NT-proBNP; bioMérieux, Lyons, France). The clinical caregivers were blinded to the NT-proBNP values in order to avoid changes to the clinical interventions based on the results. The red blood cell count (RBC), hemoglobin level (Hb), white blood cell (WBC) count, and neutrophil count (Neu) were determined using a Sysmex XE-2100 Automated Hematological Parameters Analyzer (Sysmex Corporation, Kobe, Japan).

The scientists found that NT-proBNP levels were significantly higher in patients with elevated blood glucose of greater than 7.8 mmol/L and increased white blood cell counts of greater than 14 × 109/L. HFMD patients who had no complications had significantly lower NT-proBNP values than patients who died or had complications. The team was able to discriminate between patients with and without brainstem encephalitis, pulmonary edema, pulmonary hemorrhage, circulatory failure, and death, respectively, using NT-proBNP. An NT-proBNP cut-off value of equal to or greater than 1,300 pg/mL demonstrated a high sensitivity of 85% and specificity of 93.5% for predicting death in critical HFMD patients. Children with severe EV71-associated HFMD and NT-proBNP measurements of greater than 1,300 pg/mL had significantly worse overall survival compared to those with levels less than 1,300 pg/mL.

The authors concluded that with the WBC count and blood glucose level, the NT-proBNP level can reflect the severity of EV71-associated HFMD, and NT-proBNP appears to be a better biomarker than the WBC count or hyperglycemia to discriminate severe HFMD patients with or without severe complications. NT-proBNP levels may be able to predict complications or mortality in children with severe EV71-associated HFMD disease in the intensive care unit. The study was published on November 3, 2016, in the International Journal of Infectious Diseases.

Related Links:
Hunan Children's Hospital
bioMérieux
Sysmex
Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.